Results 31 to 40 of about 143,254 (260)

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk   +10 more
wiley   +1 more source

Referral Patterns and Diagnostic Timeliness in Pediatric Cancer: A Hospital‐Based Study in Indonesia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Timely diagnosis and treatment are critical for improving survival among children with cancer. In low‐ and middle‐income countries (LMICs), delays are common and may be influenced by fragmented referral pathways and diagnostic limitations.
Nur Melani Sari   +5 more
wiley   +1 more source

Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice

open access: yesHepatology, EarlyView., 2022
Graphical summary of obesity‐induced NASH progression by LCN2 targeted to HSC activation. Abstract Background and Aims In obesity and type 2 diabetes mellitus, leptin promotes insulin resistance and contributes to the progression of NASH via activation of hepatic stellate cells (HSCs).
Kyung Eun Kim   +12 more
wiley   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Therapeutic options in peripheral T cell lymphoma

open access: yesJournal of Hematology & Oncology, 2016
Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes.
Yaping Zhang   +3 more
doaj   +1 more source

Mitochondrial translation and coordinated cytosolic translation in metabolic homeostasis and disease

open access: yesFEBS Letters, EarlyView.
Mitochondrial function depends on coordinated protein production from the nuclear and mitochondrial genomes. This review highlights how cytosolic and mitochondrial translation, mRNA localization, protein import, and respiratory complex assembly are integrated to maintain mitochondrial proteostasis and function.
Boseon Kim   +4 more
wiley   +1 more source

Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas

open access: yesLeukemia Research Reports
T-cell lymphomas are aggressive neoplasms characterized by poor responses to current chemotherapeutic agents. Expression of the l-type amino acid transporter 1 (LAT 1, SLC7A5) allows for the expansion of healthy T-cell counterparts, and upregulation of ...
Carlos Murga-Zamalloa   +10 more
doaj   +1 more source

Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

open access: yesExperimental Hematology & Oncology, 2020
Peripheral T-cell lymphomas (PTCLs) are biologically and clinically heterogeneous diseases almost all of which are associated with poor outcomes. Recent advances in gene expression profiling that helps in diagnosis and prognostication of different ...
Caiqin Xie   +3 more
doaj   +1 more source

Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells

open access: yesMolecular Oncology, EarlyView.
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts   +15 more
wiley   +1 more source

Peripheral T-Cell Lymphomas [PDF]

open access: yesEgyptian Journal of Hematology and Bone Marrow Transplantation, 2016
Nodal peripheral T cell lymphomas (TCL) are rare entities with poor prognosis including ALK+ and ALK- systemic anaplastic T-cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma – not otherwise specified. The role of PET in TCL is less well established compared to other lymphoma entities.
Maria K. Angelopoulou   +2 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy